CARY, N.C.--(BUSINESS WIRE)--Project Data Sphere®, LLC (PDS), an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), has appointed David Handelsman Vice President of Development, where he will collaborate with industry and academia that provide cancer patient clinical trial data to the PDS library-laboratory that forms the font from which new cancer discoveries are being made.
“Dave is responsible for furthering the powerful cancer research role of the Project Data Sphere initiative,” said Dr. Martin J. Murphy, CEO, Project Data Sphere, LLC. “Dave’s relevant expertise in clinical trial data and his patient focus will help advance cancer research on behalf of patients.”
Handelsman’s healthcare and life sciences expertise derives from more than 25 years of industry experience. Prior to joining Project Data Sphere, LLC, he served as Senior Director of Industry Strategy for d-Wise where his contributions focused on clinical trials and the importance of patient privacy through anonymization. Handelsman also has practical experience in addressing the European Medicines Agency (EMA) Policy 0070 on the publication of clinical data.
Before d-Wise, Handelsman was a leading contributor to the SAS Clinical Trial Data Transparency team, and prior to SAS he led data management and biostatistical teams in the US and Germany for Pharmaceutical Research Associates (PRA) and ClinTrials (Inveresk) Research. Handelsman was recently chair of the Clinical Data Interchange Standards Consortium (CDISC) Advisory Council.
More than 1,300 authorized researchers work on the Project Data Sphere platform that provides free access to clinical trial datasets across core cancer tumor types including breast, colorectal, gastric, head & neck, kidney, liver, lung, melanoma, ovarian, pancreatic and prostate cancer. To realize the full potential of these data, PDS teamed with SAS, a leader in data and health analytics, that developed and hosts the website and provides free of charge the SAS Analytic Tools to all registered users of Project Data Sphere, LLC. SAS is a charter Member of the CEO Roundtable on Cancer.
A growing compendium of more than a dozen peer-reviewed publications further demonstrates Project Data Sphere’s impact, including a recent manuscript published in a Nature journal.
The progress propelled by the Project Data Sphere platform is made possible with data providers that include: Amgen, AstraZeneca, Bayer, Celgene, EMD Serono, Janssen, Eli Lilly, Memorial Sloan Kettering Cancer Center, Millennium-the Takeda Oncology Company, Pfizer, Sanofi, Synta and The Alliance for Clinical Trials in Oncology, one of five US research groups of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN).
About Project Data Sphere®, LLC
Project Data Sphere®, LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium, operates the Project Data Sphere platform which provides one place where the research community can broadly share, integrate and analyze historical, patient-level cancer phase III comparator-arm data with the goal of advancing future research to improve the lives of cancer patients and their families around the world. For more information, visit www.ProjectDataSphere.org, or follow the Project Data Sphere initiative on Twitter at https://twitter.com/ProjectDataSphere.
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard™ which calls for organizations to evaluate their health benefits and workplace culture and take extensive, concrete actions in five key areas of health and wellness to address cancer in the workplace. The Life Sciences Consortium (www.ceo-lsc.org) was formed by the CEO Roundtable on Cancer as a means of bringing together leading oncology pharmaceutical/biotechnology companies to enable a transformation in research and development activities. For more information, please visit www.CEORoundtableOnCancer.org.
